دورية أكاديمية
A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
| العنوان: | A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. |
|---|---|
| المؤلفون: | van der Lubbe PA; University Hospital, Department of Rheumatology, Leiden, The Netherlands., Dijkmans BA, Markusse HM, Nässander U, Breedveld FC |
| المصدر: | Arthritis and rheumatism [Arthritis Rheum] 1995 Aug; Vol. 38 (8), pp. 1097-106. |
| نوع المنشور: | Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 0370605 Publication Model: Print Cited Medium: Print ISSN: 0004-3591 (Print) Linking ISSN: 00043591 NLM ISO Abbreviation: Arthritis Rheum Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: Atlanta [etc.] Arthritis Foundation [etc.] |
| مواضيع طبية MeSH: | Antibodies, Monoclonal/*therapeutic use , Arthritis, Rheumatoid/*therapy , CD4 Antigens/*immunology, Adolescent ; Adult ; Aged ; Arthritis, Rheumatoid/immunology ; Blood Cell Count ; CD4-Positive T-Lymphocytes/cytology ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Pain Measurement ; Placebos ; Time Factors |
| مستخلص: | Objective: To assess the efficacy of the CD4 monoclonal antibody (MAb) cM-T412 in the treatment of early rheumatoid arthritis (RA). Methods: Sixty patients were enrolled in a 6-week randomized, double-blind, placebo-controlled study investigating multiple dose regimens of cM-T412. Thirty patients subsequently were enrolled in a 9-month randomized, double-blind, placebo-controlled study investigating monthly single-dose administrations of cM-T412. Results: Analysis of clinical parameters revealed no changes in arthritis activity in the groups that received CD4 MAb or the placebo group, and no difference between the groups, in either in the first or the second part of the study. The number of circulating CD4+ cells decreased substantially in the patients treated with CD4 MAb. Conclusion: CD4 MAb treatment of patients with early RA induced no therapeutic effect. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (CD4 Antigens) 0 (Placebos) |
| تواريخ الأحداث: | Date Created: 19950801 Date Completed: 19950914 Latest Revision: 20220409 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1002/art.1780380812 |
| PMID: | 7639806 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0004-3591 |
|---|---|
| DOI: | 10.1002/art.1780380812 |